Sara Tolaney, MD, Dana Farber Cancer Institute, Boston, MA, discusses the preliminary results from an ongoing Phase I study evaluating datopotamab deruxtecan (Dato-DXd), a Trop2-directed antibody-drug conjugate (ADC) for patients with triple-negative (TNBC) breast cancer. This novel agent was associated with a response rate of over 40% in this heavily pre-treated metastatic TNBC population, and had a tolerable toxicity profile. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

свернуть